Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Late-onset junctional epidermolysis bullosa is a subtype of junctional epidermolysis bullosa (JEB) occurring in childhood or young adulthood.
Features include common findings: Fragile skin, Anonychia, Enamel hypoplasia, and Adermatoglyphia and others; and sometimes findings: Carious teeth, Excessive sweating (hyperhidrosis), Localized skin lesion, and Hypoplastic dermoepidermal hemidesmosomes and others.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Skin | 6 | Fragile skin, Abnormal blistering of the skin, Nail dystrophy |
Biomarker and diagnostic research for late-onset junctional epidermolysis bullosa has been reported in the published literature.
Phenotype severity distribution: 6 common features.
Estimated prevalence: <1 in 1,000,000 (VERY_RARE).
No clinical trials have been registered for late-onset junctional epidermolysis bullosa.
49 publications have been identified in PubMed for late-onset junctional epidermolysis bullosa. Research spans Basic Science / Preclinical (37%), Review / Meta-Analysis (22%), and Clinical Trial Publication (18%).
Research Type | Count | % of Total |
|---|---|---|
Laboratory research | 18 | 37% |
Data assembled from 4 of 12 sources · Last updated Sep 20, 2026, 6:06 PM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Research summaries
11 |
22% |
Clinical study results | 9 | 18% |
Disease patterns and progression | 6 | 12% |
Testing and diagnosis research | 2 | 4% |
New treatment approaches | 2 | 4% |
Patient case studies | 1 | 2% |
Mohanta SK (2025). [PMID: 40403115](https://pubmed.ncbi.nlm.nih.gov/40403115/). *Circ Res*. [Review / Meta-Analysis]
Zheng B (2025). [PMID: 38615740](https://pubmed.ncbi.nlm.nih.gov/38615740/). *J Adv Res*. [Basic Science / Preclinical]
Hracs L (2025). [PMID: 40307548](https://pubmed.ncbi.nlm.nih.gov/40307548/). *Nature*. [Epidemiology / Natural History]
Yu H (2025). [PMID: 39933468](https://pubmed.ncbi.nlm.nih.gov/39933468/). *Phytomedicine*. [Basic Science / Preclinical]
Peng YC (2025). [PMID: 39729782](https://pubmed.ncbi.nlm.nih.gov/39729782/). *Phytomedicine*. [Basic Science / Preclinical]
Falcão AS (2025). [PMID: 40427478](https://pubmed.ncbi.nlm.nih.gov/40427478/). *Antioxidants (Basel)*. [Review / Meta-Analysis]
Wei Z (2025). [PMID: 40672377](https://pubmed.ncbi.nlm.nih.gov/40672377/). *Front Pharmacol*. [Basic Science / Preclinical]
Avraham-Davidi I (2025). [PMID: 41384492](https://pubmed.ncbi.nlm.nih.gov/41384492/). *Elife*. [Basic Science / Preclinical]
Hwang PY (2025). [PMID: 41323575](https://pubmed.ncbi.nlm.nih.gov/41323575/). *Med X*. [Basic Science / Preclinical]
Normanno N (2025). [PMID: 39833354](https://pubmed.ncbi.nlm.nih.gov/39833354/). *Nat Rev Clin Oncol*. [Review / Meta-Analysis]